MicroRNA-26b attenuates monocrotaline-induced pulmonary vascular remodeling via targeting connective tissue growth factor (CTGF) and cyclin D1 (CCND1)
Metrics: PDF 1658 views | HTML 2087 views | ?
Ran Wang1,*, Xing Ding1,*, Sijing Zhou2, Min Li3, Li Sun1, Xuan Xu4, Guanghe Fei1
1Department of Respiratory Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
2Department of Occupational Diseases, Hefei Third Clinical College, Anhui Medical University, Hefei 230001, China
3Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
4Division of Pulmonary/Critical Care Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
*These authors have contributed equally to this work
Guanghe Fei, email: [email protected]
Keywords: miR-26b, CTGF, cyclin D1, monocrotaline, pulmonary hypertension
Received: December 05, 2015 Accepted: May 17, 2016 Published: June 17, 2016
MicroRNAs are involved in the control of cell growth, and deregulated pulmonary artery smooth muscle cell proliferation plays an essential role in the development of pulmonary hypertension. The objective of this study was to identify differentially expressed microRNA(s) and explore its therapeutic role in treatment of the disease. MicroRNA expression profile analysis showed microRNA-26b was differentially expressed in pulmonary artery smooth muscle cells harvested from monocrotaline-treated rats, and we validated microRNA-26b targets, in vitro and in vivo, CTGF and CCND1, both of which have been shown, in our previous work, to be involved in the pathogenesis of pulmonary hypertension. In vivo experiments demonstrated monocrotaline-induced pulmonary artery remodeling could be almost completely abolished by administration of microRNA-26b, while CTGF or CCND1 shRNA significantly, but only partially, attenuated the remodeling by silencing the designed target. Additionally, exogenous expression of the microRNA-26b substantially downregulated CTGF and CCND1 in human pulmonary artery smooth muscle cells. MicroRNA-26b might be a potent therapeutic tool to treat pulmonary hypertension.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.